Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Johnson & Johnson forecasts as much as 6% sales growth in 2024

Published Dec 05, 2023 07:17AM ET Updated Dec 05, 2023 12:06PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Johnson & Johnson company offices are shown in Irvine, California, U.S., October 14, 2020. REUTERS/Mike Blake
 
JNJ
+1.11%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Patrick Wingrove and Bhanvi Satija

(Reuters) -Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for 2024, its first full year after hiving off its consumer health unit, on strong demand for cancer treatments Darzalex and Carvykti, and blockbuster psoriasis drug Stelara.

The company also forecast 2024 adjusted operating profit of $10.55 to $10.75 per share, including a 15-cent impact from its recent acquisition of private medical device maker Laminar.

"I think they can earn closer to $10.85 vs the $10.55-10.75 guidance," said Jeff Jonas, portfolio manager at Gabelli Funds, adding the company's profit per share target is "always very conservative."

Sales of Stelara in Europe are expected to come under pressure as a key patent on the drug expires next year. Stelara is also expected to face competition in the United States beginning in 2025.

J&J (NYSE:JNJ) Chief Financial Officer Joseph Wolk said the company, which is now focusing on its drugs and medical devices business, was "very well positioned" even with some Stelara biosimilars launching outside the United States in mid-to-second half of 2024.

The company expects operational revenue, excluding COVID vaccine, to grow at a compounded annual rate of 5-7% between 2025 and 2030.

Jonas said J&J will face challenges in 2025 and beyond - and "might need another acquisition or two" to help fill the sales gap from patent expirations.

J&J, which reiterated its goal of $57 billion in drug sales in 2025, said it plans to seek regulatory approvals for at least 20 new therapies and expanded use of 50 treatments by 2030.

J&J's "lofty" long-term targets for its pharmaceutical unit are "potentially achievable" with new key products, UBS analyst Danielle Antalffy said in a note.

The company said over 10 of its products had the potential to generate more than $5 billion in peak year sales - including newer cancer treatments Talvey and Tecvayli.

Johnson & Johnson forecasts as much as 6% sales growth in 2024
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email